About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 38 results
Filters: Keyword is Young Adult  [Clear All Filters]
2017
K. L. Syrjala, Sutton, S. K., Jim, H. S. L., Knight, J. M., Wood, W. A., Lee, S. J., Jacobsen, P. B., Abidi, M. H., and Yi, J. C., Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis., Cancer, vol. 123, no. 8, pp. 1416-1423, 2017.
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes., J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
M. Arora, Weisdorf, D. J., Shanley, R. M., and Thyagarajan, B., Pharmacogenetics of steroid-responsive acute graft-versus-host disease., Clin Transplant, vol. 31, no. 5, 2017.
M. Abu Zaid, Wu, J., Wu, C., Logan, B. R., Yu, J., Cutler, C., Antin, J. H., Paczesny, S., and Choi, S. Won, Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT., Blood, vol. 129, no. 2, pp. 162-170, 2017.
J. R. Wingard, Wood, W. A., Martens, M., Le-Rademacher, J., Logan, B., Knight, J. M., Jacobsen, P. B., Jim, H., Majhail, N. S., Syrjala, K., J Rizzo, D., and Lee, S. J., Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902)., Biol Blood Marrow Transplant, vol. 23, no. 1, pp. 161-164, 2017.
M. Eapen, Kurtzberg, J., Zhang, M. - J., Hattersely, G., Fei, M., Mendizabal, A., Chan, K. Wah, De Oliveira, S., Schultz, K. R., Wall, D., Horowitz, M. M., and Wagner, J. E., Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes., Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
S. A. Holstein, Jung, S. - H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., van Besien, K., Gentile, T. G., Isola, L., Maziarz, R. T., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Rodriguez, C., McClune, B., Schlossman, R. L., Smith, S. E., Hars, V., Owzar, K., Jiang, C., Boyd, M., Schultz, C., Wilson, M., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Linker, C., Anderson, K. C., and McCarthy, P. L., Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial., Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.
2016
J. C. Alvarnas, Le Rademacher, J., Wang, Y., Little, R. F., Akpek, G., Ayala, E., Devine, S., Baiocchi, R., Lozanski, G., Kaplan, L., Noy, A., Popat, U., Hsu, J., Morris, L. E., Thompson, J., Horowitz, M. M., Mendizabal, A., Levine, A., Krishnan, A., Forman, S. J., Navarro, W. H., and Ambinder, R., Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial., Blood, vol. 128, no. 8, pp. 1050-8, 2016.
J. M. Knight, Syrjala, K. L., Majhail, N. S., Martens, M., Le-Rademacher, J., Logan, B. R., Lee, S. J., Jacobsen, P. B., Wood, W. A., Jim, H. S. L., Wingard, J. R., Horowitz, M. M., Abidi, M. H., Fei, M., Rawls, L., and J Rizzo, D., Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial., Biol Blood Marrow Transplant, vol. 22, no. 12, pp. 2256-2263, 2016.
L. J. Burns, Logan, B. R., Chitphakdithai, P., Miller, J. P., Drexler, R., Spellman, S., Switzer, G. E., Wingard, J. R., Anasetti, C., and Confer, D. L., Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201., Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1108-1116, 2016.
H. S. L. Jim, Sutton, S. K., Small, B. J., Jacobsen, P. B., Wood, W. A., Knight, J. M., Majhail, N. S., Syrjala, K. L., and Lee, S. J., Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data., Biol Blood Marrow Transplant, vol. 22, no. 11, pp. 2077-2083, 2016.
W. W. Hope, Walsh, T. J., Goodwin, J., Peloquin, C. A., Howard, A., Kurtzberg, J., Mendizabal, A., Confer, D. L., Bulitta, J., Baden, L. R., Neely, M. N., and Wingard, J. R., Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial., J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.